Citigroup Lowers HCA Healthcare (NYSE:HCA) Price Target to $254.00

HCA Healthcare (NYSE:HCAGet Rating) had its price objective decreased by stock analysts at Citigroup from $277.00 to $254.00 in a report released on Monday, April 25th, Marketbeat reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price objective suggests a potential upside of 12.99% from the stock’s previous close.

HCA has been the subject of a number of other research reports. Wells Fargo & Company initiated coverage on shares of HCA Healthcare in a research report on Monday, March 28th. They set an “equal weight” rating and a $267.00 target price for the company. StockNews.com upgraded shares of HCA Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 6th. Truist Financial boosted their price objective on shares of HCA Healthcare from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, January 5th. Cowen decreased their price objective on shares of HCA Healthcare from $302.00 to $265.00 and set an “outperform” rating for the company in a research note on Friday, January 28th. Finally, Credit Suisse Group decreased their price objective on shares of HCA Healthcare from $296.00 to $260.00 and set an “outperform” rating for the company in a research note on Monday, April 25th. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, HCA Healthcare has a consensus rating of “Buy” and a consensus price target of $259.27.

NYSE HCA traded up $8.50 during trading hours on Monday, hitting $224.80. 2,086,485 shares of the company’s stock were exchanged, compared to its average volume of 1,762,744. The business’s 50 day moving average is $252.11 and its 200-day moving average is $247.55. HCA Healthcare has a 12-month low of $199.76 and a 12-month high of $279.02. The firm has a market capitalization of $67.89 billion, a P/E ratio of 10.18, a price-to-earnings-growth ratio of 1.29 and a beta of 1.60. The company has a debt-to-equity ratio of 87.46, a quick ratio of 1.24 and a current ratio of 1.43.

HCA Healthcare (NYSE:HCAGet Rating) last released its earnings results on Friday, April 22nd. The company reported $4.12 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $4.25 by ($0.13). HCA Healthcare had a return on equity of 405.72% and a net margin of 11.40%. The business had revenue of $14.95 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter last year, the company posted $4.14 earnings per share. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. As a group, equities research analysts anticipate that HCA Healthcare will post 17.15 EPS for the current fiscal year.

HCA Healthcare announced that its board has authorized a stock repurchase plan on Thursday, January 27th that allows the company to buyback $8.00 billion in shares. This buyback authorization allows the company to reacquire up to 10.9% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

In other news, SVP Michael R. Mcalevey purchased 1,110 shares of the stock in a transaction dated Friday, April 29th. The stock was acquired at an average price of $218.56 per share, for a total transaction of $242,601.60. Following the completion of the transaction, the senior vice president now owns 1,110 shares of the company’s stock, valued at $242,601.60. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Andrea B. Smith purchased 1,160 shares of the stock in a transaction dated Thursday, April 28th. The shares were purchased at an average price of $213.63 per share, with a total value of $247,810.80. Following the transaction, the director now directly owns 2,239 shares of the company’s stock, valued at approximately $478,317.57. The disclosure for this purchase can be found here. 1.50% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of HCA. Equitec Proprietary Markets LLC acquired a new stake in HCA Healthcare in the 4th quarter valued at about $26,000. Baltimore Washington Financial Advisors Inc. purchased a new stake in HCA Healthcare during the fourth quarter valued at about $26,000. GoalVest Advisory LLC purchased a new stake in HCA Healthcare during the first quarter valued at about $26,000. Amplius Wealth Advisors LLC purchased a new stake in shares of HCA Healthcare in the fourth quarter worth approximately $27,000. Finally, PYA Waltman Capital LLC purchased a new stake in shares of HCA Healthcare in the fourth quarter worth approximately $31,000. 67.87% of the stock is owned by institutional investors.

About HCA Healthcare (Get Rating)

HCA Healthcare, Inc, through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

See Also

Analyst Recommendations for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.